Please assess the completion status of the following clinical trial:

Trial Title: Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-35 years (both included)~* Regular Menses (between 25-35 days)~* Absence of physical and psychic pathologies at the time of oocyte donation~* BMI: 18-28 kg(m2 at the time of oocyte donation.~* Other criteria to comply with:~  i. With no relevant personal or family medical history ii. Signing of Informed Consent iii. From a medical point of view:~ 1. Healthy ovaries and uterus, with no organic pathology~ 2. Ovaries without polycystic aspect~ 3. Antral Follicle Count \> 12 in the sum of both ovaries~ 4. Normal Karyotype~ 5. Negative results in infectious illness screening (Hepatitis B Virus; Hepatitis C Virus, VIH Virus Syphilis)~ 6. Results within range of general analysis of hemogram, hemostasia y biochemistry.~     Exclusion Criteria:~* Any systemic or metabolic disorder which contraindicate the use of Gonadotrophines~* Medical background of Trombophlebitis or thromboembolic phenomena or Arterial Hypertension~* Severe hepatic insufficiency, cardiovascular illness~* Suspicion or evidence of malignity of mamarian glands or other hormone dependant genital organs~* Known infection of Hepatitis B Virus; Hepatitis C Virus or VIH Virus~* Known hypersensitivity to PMA or its excipients~* Any reason or cause which excluede from the oocyte donation program~* Participation in another clinical trial in the two months prior to the inclusion on this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Provera (Type: EXPERIMENTAL): None
- Orgalutrán Ganirelix (GnRH antagonist) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).